Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Doberan – page 11

214 clinical trials in Bad Doberan, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Doberan at a glance
214
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

214 trials in Bad Doberan

Open in trial search

Testing continuous versus intermittent treatment with cetuximab, fluorouracil, folinic acid, and irinotecan in patients with newly diagnosed metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Dementia Alzheimer's type

Not yet recruiting

Study on Thiethylperazine and Florbetaben (18F) for Early Alzheimer's Disease Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florbetaben (18F)
  • Sponsor:Immungenetics AG

Prostate cancer

Not yet recruiting

Study on the Safety and Effectiveness of SpectraCure P18 System and Verteporfin for Treating Localized Prostate Cancer in Men

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:SpectraCure AB (publ)

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Dementia Alzheimer's type

Not yet recruiting

Study on the Safety and Effectiveness of PRI-002 for Patients with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:D-Prolyl-D-Threonyl-D-Leucyl-D-Histidyl-D-Threonyl-D-Histidyl-D-Asparaginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginyl-D-Arginine Amide Acetate
  • Sponsor:Prinnovation GmbH

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study of Cytarabine and Daunorubicin for Treating Myeloid Leukemia in Children with Down Syndrome

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cytarabine
  • Sponsor:GPOH gGmbH

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Doberan

What the registry says about research in the country

01 Arthritis Studies

Investigating novel treatments for psoriatic arthritis, with multiple trials evaluating the effectiveness of new biological therapies. Research focuses on patients who haven't previously received biological medicines, as well as long-term safety assessments.

  • Zasocitinib evaluation
  • Bimekizumab long-term study

These trials aim to improve treatment options for patients with active disease forms.

02 Osteoarthritis Research

Comprehensive studies on knee osteoarthritis examining both acute and chronic pain management. Research includes evaluation of novel compounds for pain relief and functional improvement.

  • DFV890 efficacy testing
  • ODM-111 chronic pain study

Focus on developing treatments that could provide meaningful pain relief for patients.

03 Autoimmune Conditions

Innovative research into various autoimmune conditions, including Sjögren's Syndrome and Giant Cell Arteritis. Studies evaluate new therapeutic approaches for managing systemic manifestations.

  • Dazodalibep safety studies
  • Secukinumab treatment trials
  • Spondyloarthritis research

These trials aim to develop more effective treatments for complex autoimmune disorders.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.